This post is from a suggested group

As per Data Bridge Market Research analysis, the bendamustine market was valued at USD 786.00 million in 2025 and is projected to reach USD 1,188.09 million by 2033, growing at a CAGR of 5.30% from 2026 to 2033.
The market is experiencing consistent growth driven by the rising prevalence of hematological malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), increasing demand for effective chemotherapy treatments, and expanding use of bendamustine-based combination therapies.
